NYU researchers identify new potential therapeutic target for diffuse large B-cell lymphoma:

NYU researchers identify new potential therapeutic target for diffuse large B-cell lymphoma:   NCI Cancer Center News Researchers from the NYU Cancer Institute, an NCI-designated cancer center at NYU Langone Medical Center, have discovered a new potential therapeutic target for Diffuse Large B-Cell Lymphoma (DLBCL), the most aggressive and common type of lymphoma in adults. … Continue reading “NYU researchers identify new potential therapeutic target for diffuse large B-cell lymphoma:”

NYU researchers identify new potential therapeutic target for diffuse large B-cell lymphoma:

 

NCI Cancer Center News

Researchers from the NYU Cancer Institute, an NCI-designated cancer center at NYU Langone Medical Center, have discovered a new potential therapeutic target for Diffuse Large B-Cell Lymphoma (DLBCL), the most aggressive and common type of lymphoma in adults. The new study, published in the November 23 issue of Nature, reveals the underlying molecular mechanism contributing to the development of lymphomagenesis.

Click here to read full press release from NYU Cancer Institute.

###

NCI cancer centers logoAmong the research institutions NCI funds across the United States, it currently designates 66 as Cancer Centers. Largely based in research universities, these facilities are home to many of the NCI-supported scientists who conduct a wide range of intense, laboratory research into cancer’s origins and development. The Cancer Centers Program also focuses on trans-disciplinary research, including population science and clinical research. The centers’ research results are often at the forefront of studies in the cancer field.

Author: Joe Lovrek

Born in Houston, Raised in Trinity Texas

Leave a Reply